Using Single-cell Sequencing of Lung Fluid to Guide Treatment for Radiation or Immune Checkpoint Inhibitor Pneumonitis in Adults with NSCLC

What this Trial Is About

Researchers are exploring radiation pneumonitis and immune checkpoint inhibitor pneumonitis in patients using single-cell sequencing of bronchoalveolar lavage fluid. The goal is to understand how these conditions develop and find ways to prevent them. This study uses a new technology to guide treatment based on findings from single-cell sequencing and treatment guidelines. Participants receive single-cell sequencing tests before treatment. Based on the results, patients are treated specifically for radiation pneumonitis or immune checkpoint inhibitor pneumonitis according to recommended guidelines. This study includes two groups, each receiving treatment tailored to their respective pneumonitis type. During the study, patients undergo bronchoalveolar lavage fluid sampling and single-cell sequencing before treatment. Researchers will monitor response rates over an 8-week period after treatment begins. Participants are evaluated regularly to track treatment effects and safety, with the study lasting up to the end date in December 2025.

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis